The opportunity
Two markets, converging.
A natural male contraceptive sits where two large, growing markets cross — and the male oral contraceptive market is still waiting for its first success story.
The global contraceptive market is around $30B and projected to roughly double by the mid-2030s. Male methods make up under a tenth of it — essentially condoms and vasectomy. Meanwhile the dietary-supplement market (~$210B) is on track to more than double this decade, its botanical segment growing near 9% a year.
A natural male contraceptive sits where those two lines cross. Several synthetic candidates are in development, but none come from a natural-products lineage. Once early safety data is in, Sovereign's preparation can reach people as a natural health product / supplement, generating revenue while clinical validation progresses toward a formal contraceptive claim.
Why now
Forces converging.
Several forces make this the moment for a natural male contraceptive — some scientific and commercial, others human and urgent.
A closing window in West Papua
The plant's traditional stewards live under real pressure — more than 107,000 people displaced by armed conflict as of early 2026. Partnership, revenue sharing, and international visibility can bring these communities much-needed support, and can help ease the economic and political factors driving the conflict.
Knowledge disappearing with language
Papua holds roughly 270 Indigenous languages, among the world's most endangered. The ethnobotanical knowledge they carry — the traditional medicine this plant comes from — is projected to be lost within the next several generations.
Reproductive rights under pressure
As reproductive options come under strain in many places, demand is rising for natural, healthier methods — and for men to share contraceptive responsibility.
A healthier model of masculinity
Men are rethinking their role in partnership and community. Sovereign supports that shift: contraception as an act of care, and responsibility genuinely shared.
A first-mover window
The nearest competitors are five to seven years from market, and none come from a natural-products lineage. The chance to establish this category is open now.
The advantage
First mover in a brand new category.
A natural-products lineage
Decades of traditional-use data, a proposed mechanism of action, and clinical research in Indonesia to build on.
Held through partnership
Engaging with the originating community — combined with novel IP strategies — creates competitive advantage no other party is building.
Investing
Pre-seed, on convertible notes.
Sovereign is raising a pre-seed round on convertible promissory notes to fund operations and proof-of-concept work, alongside research grants. Investors joining now come in early, on good terms.
Funding also lets us engage the original Indonesian research team and build relationships on the ground in Indonesia. If that research meets Western regulatory requirements, it could meaningfully accelerate development.
Full materials and methodology available under NDA.
Full pitch deck available on request.
Get involved
It takes the right people.
Invest
Pre-seed convertible notes, with favourable terms prior to proof of concept. Request the details below.
Join the team
Clinical research, regulatory, botanical medicine, corporate law, indigenous partnerships.
Connect
Know someone who should know about this? Introductions matter.
Support
Contributions help fund proof-of-concept research. GoFundMe →
Send a note
Stay in the loop
Updates on the project, and first word when protocols become available.